F2G Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Manchester United Kingdom (1998)

Organization Overview

First Clinical Trial
2014
NCT02142153
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

F2G Biotech GmbH | F2G Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Aspergillosis (Phase 2)

Communicable Diseases (Phase 2)

Infections (Phase 2)

Invasive Fungal Infections (Phase 2)

Invasive Pulmonary Aspergillosis (Phase 2)

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Mycoses (Phase 2)

Pulmonary Aspergillosis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 20
  • # of Trial APIs: 11